Tenet Healthcare Corporation (BMV:THC)
Mexico · Delayed Price · Currency is MXN | Market Cap | 408.89B +20.9% |
| Revenue (ttm) | 399.32B +6.2% |
| Net Income | 52.25B +114.1% |
| EPS | 640.74 +134.1% |
| Shares Out | n/a |
| PE Ratio | 5.54 |
| Forward PE | 13.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491 |
| Open | 3,550.22 |
| Previous Close | 3,665.00 |
| Day's Range | 3,545.22 - 3,550.22 |
| 52-Week Range | 2,547.79 - 3,995.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Tenet Healthcare
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial numbers in USD Financial StatementsNews
Tenet Healthcare price target raised to $297 from $274 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $297 from $274 and keeps an Overweight rating on the shares.
Tenet Healthcare price target raised to $300 from $285 at Raymond James
Raymond James raised the firm’s price target on Tenet Healthcare (THC) to $300 from $285 and keeps an Outperform rating on the shares. Tenet’s Q3 results were fundamentally in line,…
Tenet Healthcare price target lowered to $306 from $307 at Guggenheim
Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $306 from $307 and keeps a Buy rating on the shares as the firm updated estimates following earnings. Published…
Tenet Healthcare price target raised to $285 from $280 at Baird
Baird raised the firm’s price target on Tenet Healthcare (THC) to $285 from $280 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results…
Tenet Healthcare sees overall adjusted EBITDA growth in 2027
Comments taken from Q3 earnings conference call.
Tenet Healthcare Earnings Call Transcript: Q3 2026
Q3 revenue was $5.6B and adjusted EBITDA was $1.355B; FY26 EBITDA guidance rose to $5.05B–$5.2B. Exchange pressure persisted, while USPI growth and disciplined costs supported results and 2027 growth expectations excluding one-time Conifer transitions.
Tenet Healthcare Earnings release: Q3 2026
Tenet Healthcare released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Tenet Healthcare Slides: Q3 2026
Tenet Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Tenet Healthcare Quarterly report: Q3 2026
Tenet Healthcare has published its Q3 2026 quarterly earnings report on October 29, 2026.
Tenet Healthcare sees FY26 adjusted EPS $22.05-$23.01, consensus $21.23
Now sees FY26 revenue $22.05B-$22.45B, consensus $22.42B. FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05B to $5.2B, a $195M increase at the midpoint…
Tenet Healthcare reports Q3 adjusted EPS $6.64, consensus $4.68
Reports Q3 net revenue $5.63B, consensus $5.51B. “Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management,” said ...
Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026. "Our outperformance in the third quarter of 2026 was dri...
Tenet Healthcare price target raised to $307 from $283 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $307 from $283 and keeps a Buy rating on the shares. The firm anticipates Tenet will “stick to its…
Tenet to Report Its Third Quarter 2026 Results on October 29
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its third quarter 2026 results before the market opens on Thursday, October 29, 2026, to be followed by a conference call...
BMO starts Tenet at Market Perform, says execution reflected in valuation
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target Tenet’s expanding Ambulatory business increasingly leverages it to an end-market with more f...
Tenet Healthcare initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target
Tenet Healthcare Transcript: Wells Fargo 21st Annual Healthcare Conference
Expansion in high acuity ambulatory and hospital services is driving revenue and margin growth, supported by disciplined cost management, strategic investments, and favorable policy trends. Conifer's transformation and targeted AI investments are expected to further enhance efficiency and competitiveness.
Tenet Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notes
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $2.0 billion in ag...
Tenet Announces Private Offering of Senior Notes to Refinance $1.5 Billion in Outstanding Notes
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced a private placement offering of $1.5 billion in aggregate principal amount of new senior notes due 2034 (the “notes”) ...
Tenet to Participate in the Wells Fargo Healthcare Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, beginning at 12:45 p.m. Eastern Time...
Tenet Healthcare price target raised to $285 from $275 at Raymond James
Raymond James raised the firm’s price target on Tenet Healthcare (THC) to $285 from $275 and keeps an Outperform rating on the shares. The company’s differentiated ASC exposure, manageable Medicaid…
Tenet Healthcare price target raised to $295 from $290 at BofA
BofA raised the firm’s price target on Tenet Healthcare (THC) to $295 from $290 and keeps a Buy rating on the shares. July data points better than Q2 for foot…
Tenet Healthcare price target raised to $290 from $250 at Mizuho
Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $290 from $250 and keeps an Outperform rating on the shares. The firm cites stronger underlying performance for the…
Tenet Healthcare price target raised to $281 from $231 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Tenet Healthcare (THC) to $281 from $231 and keeps an Overweight rating on the shares. The firm cites higher…
Tenet Healthcare price target raised to $305 from $252 at Goldman Sachs
Goldman Sachs analyst Scott Fidel raised the firm’s price target on Tenet Healthcare (THC) to $305 from $252 and keeps a Buy rating on the shares. Shares have decisively outperformed…